A little more than three years ago, a Vanity Fair headline asked the question: “Is Bill Ackman Toast?” At the time, Ackman’s Pershing Square Capital hedge fund firm was sinking under its disastrous bet on Canadian pharmaceuticals rollup Valeant Pharmaceuticals International, its investors were starting to bolt, and the naysayers were writing Ackman off.
But
